Technical Analysis for MNPR - Monopar Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.65 | 3.50% | 0.02 |
MNPR closed down 4.49 percent on Thursday, April 25, 2024, on 1 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 3.59% | |
NR7 | Range Contraction | 3.59% | |
Narrow Range Bar | Range Contraction | 3.59% | |
BB Squeeze Started | Range Contraction | 3.59% | |
Wide Bands | Range Expansion | 3.59% | |
20 DMA Resistance | Bearish | -1.07% | |
Wide Bands | Range Expansion | -1.07% | |
Gapped Up | Strength | -1.07% | |
Wide Bands | Range Expansion | 0.00% | |
Narrow Range Bar | Range Contraction | 2.85% |
Alert | Time |
---|---|
Up 3% | 35 minutes ago |
Up 2% | 35 minutes ago |
Up 1% | 35 minutes ago |
Possible NR7 | about 20 hours ago |
60 Minute Opening Range Breakdown | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.75 |
52 Week Low | 0.2739 |
Average Volume | 6,801,439 |
200-Day Moving Average | 0.57 |
50-Day Moving Average | 0.75 |
20-Day Moving Average | 0.66 |
10-Day Moving Average | 0.68 |
Average True Range | 0.08 |
RSI (14) | 44.13 |
ADX | 10.21 |
+DI | 23.48 |
-DI | 26.41 |
Chandelier Exit (Long, 3 ATRs) | 0.60 |
Chandelier Exit (Short, 3 ATRs) | 0.75 |
Upper Bollinger Bands | 0.77 |
Lower Bollinger Band | 0.56 |
Percent B (%b) | 0.33 |
BandWidth | 32.06 |
MACD Line | -0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0039 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.67 | ||||
Resistance 3 (R3) | 0.68 | 0.66 | 0.67 | ||
Resistance 2 (R2) | 0.66 | 0.65 | 0.66 | 0.66 | |
Resistance 1 (R1) | 0.65 | 0.64 | 0.64 | 0.64 | 0.66 |
Pivot Point | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
Support 1 (S1) | 0.62 | 0.62 | 0.61 | 0.61 | 0.60 |
Support 2 (S2) | 0.60 | 0.61 | 0.60 | 0.59 | |
Support 3 (S3) | 0.59 | 0.60 | 0.59 | ||
Support 4 (S4) | 0.58 |